1. A multi-disciplinary approach to delivering PCSK9 inhibitor therapy – first 12 months experience at a specialist cardiothoracic centre. (August 2018) Authors: Hayes, C.; Browne, C.; Neves, E.; Breen, J.; Priestley-barnham, L.; Davis, L.; Pottle, A.; Thompson, K.; Manning, S.; Barbir, M. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A qualitative study exploring the patient experience of treatment with PCSK9 monoclonal antibodies. (December 2020) Authors: Neves, E.; Browne, C.; Barbir, M. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Coronary artery surgery in women compared with men: analysis of coronary risk factors and in-hospital mortality in a single centre. Issue 5 (May 1994) Authors: Barbir, M.; Lazem, F.; Ilsley, C.; Mitchell, A.; Khaghani, A.; Yacoub, M. Journal: Heart Issue: Volume 71:Issue 5(1994) Page Start: 408 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of combination therapy with pcsk9 inhibitors and lipoprotein apheresis. (September 2018) Authors: Pottle, A.; Browne, C.; Neves, E.; Barbir, M. Journal: Atherosclerosis Issue: Volume 34(2018) Page Start: e9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Homozygous Familial Hypercholesterolaemia – Summary of cases detected at the Bristol Genetics Laboratory. (February 2016) Authors: Hills, A.; Honeychurch, J.; Dean, P.; Dennis, G.; Greenslade, M.; Barbir, M.; Breen, J.; Dawson, C.; El-Farhan, N.; Ayling, R.; Sharma, A.; Bayly, G.; Williams, M. Journal: Atherosclerosis Issue: Volume 245(2016) Page Start: e249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Homozygous Familial Hypercholesterolaemia – Summary of cases detected at the Bristol Genetics Laboratory. (February 2016) Authors: Hills, A.; Honeychurch, J.; Dean, P.; Dennis, G.; Greenslade, M.; Barbir, M.; Breen, J.; Dawson, C.; El-Farhan, N.; Ayling, R.; Sharma, A.; Bayly, G.; Williams, M. Journal: Atherosclerosis Issue: Volume 245(2016) Page Start: e249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. If you don't diagnose familial hypercholesterolaemia (FH) the pathologist will. (December 2020) Authors: Priestley-Barnham, L.; Breen, J.; Browne, C.; Davis, L.; Huggett, C.; Khan, T.; Neves, E.; Barbir, M. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Inject away: The Harefield experience on delivering the new PCSK9 inhibitors. (September 2017) Authors: Browne, C.; Neves, E.; Breen, J.; Davies, L.; Priestley-Barnham, L.; Pottle, A.; Hayes, C.; Thompson, K.; Barbir, M. Journal: Atherosclerosis Issue: Volume 28(2017) Page Start: e12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Lipoprotein apheresis in pregnancy. (December 2020) Authors: Pottle, A.; Khan, T.; Barbir, M. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Oxidised LDL and Anti-oxidised LDL antibodies are reduced by lipoprotein apheresis in a randomised controlled trial on patients with refractory angina and elevated lipoprotein(A). (August 2018) Authors: Khan, T.Z.; Haskard, D.; Caga-Anan, M.; Pennell, D.J.; Barbir, M.; Khamis, R. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗